Federal health scientists say follow-up studies of the breast cancer drug Avastin show it did not slow tumor growth to the same degree as reported in earlier studies or extend patient lives.
The Food and Drug Administration gave Roche's blockbuster drug conditional approval two years ago based on early-stage...
more »